# A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL

Source: https://onco.cc/trials/nct05806099/  
OnCo record `nct05806099` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of MBS303 in non-Hodgkin lymphoma, run by Beijing Mabworks Biotech Co., Ltd., now recruiting.

## Summary

A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy Study of MBS303 in B-Cell NHL is a phase 1/2 interventional study registered as NCT05806099 by Beijing Mabworks Biotech Co., Ltd., with 132 participants planned, started 2023-06-28 and due to reach its primary completion in 2025-11. Interventions recorded: MBS303.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05806099
- Phase: 1/2
- Setting: A Phase I/Ⅱ Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of MBS303 in Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Sponsor: Beijing Mabworks Biotech Co., Ltd.
- Enrolled: 132

## Sources

- ClinicalTrials.gov NCT05806099: https://clinicaltrials.gov/study/NCT05806099

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- companies: [Beijing Mabworks Biotech](https://onco.cc/companies/beijing-mabworks-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct05806099.json